Companies · Pharmaceuticals

Aceto Management, L.L.C.

NEW YORK · Pharmaceuticals

Diligence memoA one-page analyst read on Aceto Management, L.L.C. — recommendation, valuation, rhythm, risks.
$23.6M
Total raised · real
1
Rounds
1.1×
Latest step-up
Top 32%
Sector rank · raised
Series B
Latest stage · inferred · Wed Oct 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Aceto Management, L.L.C. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.62× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.7 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Aceto Management, L.L.C. is one of 1613 Pharmaceuticals companies tracked from NEW YORK. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
19
Investors (latest)
2019
Year incorporated
2019-10-16
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2019-10-16 Raised $21M (real) Modeled valuation $722M (est)$21M$722MSeries B2019Series B · 2019-10-16 Raised $24M (real) Modeled valuation $803M (est)$24M$803MSeries B2019+$24MCumulative $45M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$21.2M · 2019
Series B extension$23.6M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$803.2M
Base estimate est.
$49.6M
Conservative case
$3.1B
Upside case
$131.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series B · modeled $722.2M · 2019-10-162019Series B · modeled $803.2M · 2019-10-162019
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
57%
Survival probability
38% low · 70% high
1.49×/yr
Annual markup
1.80×/yr upside case
6.0 yr
Elapsed time used
6.7 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
6.7 yr
On record since
2019
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.9× above median
This company$23.6M
Sector median$8.1M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.3× above median
This company$23.6M
Sector median$18.0M
Modeled value — vs sector median (estimate, all stages) 11× above median
This company$803.2M
Sector median$76.1M

Raised more than 69% of sector peers (real $). Modeled value above 87% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #9 of 61.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Evolus, Inc. · Series B Raised $40.5M · modeled $1.4B (est)HOOKIPA Pharma Inc. · Series B Raised $37.4M · modeled $1.3B (est)ESSA Pharma Inc. · Series B Raised $56.0M · modeled $1.2B (est)Pieris Pharmaceuticals, Inc. · Series B Raised $102.1M · modeled $1.1B (est)Amylyx Pharmaceuticals, Inc. · Series B Raised $65.1M · modeled $1.0B (est)PassPort Technologies, Inc. · Series B Raised $30.0M · modeled $1.0B (est)Savara Inc · Series B Raised $30.9M · modeled $910.6M (est)InCarda Therapeutics, Inc. · Series B Raised $66.3M · modeled $857.5M (est)GPI Finco (Canada) Inc. · Series B Raised $22.9M · modeled $778.0M (est)Phosplatin Therapeutics LLC · Series B Raised $72.3M · modeled $722.8M (est)Lannett Co Inc · Series B Raised $28.0M · modeled $691.3M (est)Aceto Management, L.L.C. (this company) Raised $23.6M · modeled $803.2M (est)Aceto Management, L.L.C.
CompanyStageRaised · realValue · estvs peer med.
Evolus, Inc.Series B$40.5M$1.4B2.74×
HOOKIPA Pharma Inc.Series B$37.4M$1.3B2.57×
ESSA Pharma Inc.Series B$56.0M$1.2B2.47×
Pieris Pharmaceuticals, Inc.Series B$102.1M$1.1B2.20×
Amylyx Pharmaceuticals, Inc.Series B$65.1M$1.0B2.06×
PassPort Technologies, Inc.Series B$30.0M$1.0B2.06×
Savara IncSeries B$30.9M$910.6M1.84×
InCarda Therapeutics, Inc.Series B$66.3M$857.5M1.73×
Aceto Management, L.L.C. this companySeries B$23.6M$803.2M1.62×
GPI Finco (Canada) Inc.Series B$22.9M$778.0M1.57×
Phosplatin Therapeutics LLCSeries B$72.3M$722.8M1.46×
Lannett Co IncSeries B$28.0M$691.3M1.40×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$21.2M2019-10-16$118.0M$722.2M90%
Series B$23.6M2019-10-16$131.2M$803.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$21.2M2019-10-16
    • First recorded raise — entered as Series B.
    • 15 investors on this round.
  2. Series B$23.6M2019-10-16
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 19 investors on this round.
Intelligence
Modeled next raise
$26.3M
Modeled next size est.range $23.6M$42.0M
1.1×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
ADAM WEINSTEIN10 other2019-10
ANDRE MOURA5 other2019-10
Joseph Walker4 other2019-10
Registry & provenance

Aceto Management, L.L.C. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1829446
SEC CIK
2019
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Bellerophon Therapeutics, Inc.PharmaceuticalsSeries B$25.0M$796.9Mnetwork2 shared operators · same sector · same stage
Citrus Partners Holdings, L.P.OtherSeries B$30.7M$238.0Mnetwork2 shared operators · same stage
Recro Pharma, Inc.PharmaceuticalsSeries B$23.8M$544.1Msame sector · same stage
Attune Pharmaceuticals, Inc.PharmaceuticalsSeries B$23.3M$793.0Msame sector · same stage
Relmada Therapeutics, Inc.PharmaceuticalsSeries B$23.2M$511.8Msame sector · same stage
La Jolla Pharmaceutical CoPharmaceuticalsSeries B$22.9M$603.8Msame sector · same stage
GPI Finco (Canada) Inc.PharmaceuticalsSeries B$22.9M$778.0Msame sector · same stage
Columbia Laboratories IncPharmaceuticalsSeries B$24.5M$834.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
ACEA Therapeutics, Inc.PharmaceuticalsSeries B$612.1M79%
Balto Pharmaceuticals, Inc.PharmaceuticalsSeed$14.9M78%
Acendrx, Inc.PharmaceuticalsSeed$95.1M78%
PharmaCielo Ltd.PharmaceuticalsSeries A$195.6M77%
Olema Pharmaceuticals, Inc.PharmaceuticalsSeries D+$2.4B76%
Balto Therapeutics, LLCPharmaceuticalsSeed$114.1M75%
Lyell Immunopharma, Inc.PharmaceuticalsGrowth/Late$17.9B75%
LGM Holdings, LLCPharmaceuticalsSeed$35.3M75%
Frequently asked
How much funding has Aceto Management, L.L.C. raised?
Aceto Management, L.L.C. has raised approximately $23.6M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Aceto Management, L.L.C.'s estimated valuation?
Provath's modeled valuation for Aceto Management, L.L.C. is approximately $803.2M (modeled range $49.6M–$3.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Aceto Management, L.L.C. at?
Aceto Management, L.L.C.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Wed Oct 16.
What does Aceto Management, L.L.C. do and where is it based?
Aceto Management, L.L.C. operates in the Pharmaceuticals sector, based in NEW YORK.
Explore related

See where Aceto Management, L.L.C. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Aceto Management, L.L.C., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.